1. Albers T, Maniak M, Beitz E, et al. The C Isoform of Dictyostelium tetraspanins localizes to the contractile vacuole and contributes to resistance against osmotic stress.
PLos ONE. 2016; 11:e0162065
2. Atkinson B, Ernst CS, Ghrist BF, et al. Immunoassay for melanoma-associated proteoglycan in the sera of patients using monoclonal and polyclonal antibodies. Cancer Res. 1984; 44:2577-2581
3. Baudy AR, Dogan T, Flores-Mercado JE, et al. FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973. EJMMI Res. 2012; 2:22
4. Berditchevski F, Bazzoni G, Hemler ME. Specific association of CD63 with the VLA-3 and VLA-6 integrins. J. Biol. Chem. 1995; 270:17784-17790
5. Berditchevski F, Zutter MM, Hemler ME. Characterization of novel complexes on the cell surface between integrins and proteins with 4 transmembrane domains (TM4 proteins). Mol. Biol Cell. 1996; 7:193-207
6. Berditchevski F, Tolias KF, Wong K, et al. A novel link between integrins, transmembrane-4 superfamily proteins (CD63 and CD81), and phosphatidylinositol 4-kinase. J. Biol. Chem. 1997; 272:2595-2598
7. Berditchevski F, Odintsova E, Sawada S, et al. Expression of the palmitoylation-deficient CD151 weakens the association of alpha 3 beta 1 integrin with the tetraspanin-enriched microdomains and affects integrin-dependent signaling. J. Biol.
Chem. 2002; 277:36991-37000
8. Berditchevski F, Odintsova E. Tetraspanins as regulators of protein trafficking. Traffic.
2006; 8:89-96
9. Boman A, Svensson S, Boxer A, et al. Distinct lysosomal network protein profiles in parkinsonian syndrome cerebrospinal fluid. J. Parkinsons. Dis. 2016; 6:307-315
10. Bommarito A, Richiusa P, Carissimi E, et al. BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy. Endocr. Relat. Cancer. 2011; 18:669-685
11. Braeuer RR, Shoshan E, Kamiya T et al. The sweet and bitter sides of galectins in melanoma progression. Pigment Cell Melanoma Res. 2012; 25:592-601
12. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011; 364:2507-2516
13. Chapman PB, Robert C, Larkin J, et al. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Ann. Oncol. 2017; 28:2581-2587
14. Charrin S, Manié S, Thiele C, et al. A physical and functional link between cholesterol and tetraspanins. Eur. J. Immunol. 2003; 33:2479-2489
15. Charrin S, Jouannet S, Boucheix C, et al. Tetraspanins at a glance. J. Cell Sci. 2014;
127:3641-3648
16. Claas C, Stipp CS, Hemler ME. Evaluation of prototype transmembrane 4 superfamily protein complexes and their relation to lipid rafts. J. Biol. Chem. 2001; 276:7974-7984
17. Codina J, Li J, Dubose TD Jr. CD63 interacts with the carboxy terminus of the colonic H+-K+-ATPase to decrease [corrected] plasma membrane localization and 86Rb+
uptake. Am. J. Physiol. Cell Physiol. 2005; 288:1279-1286
18. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer.
Nature. 2002; 417:949-954
19. Duffield A, Kamsteeg EJ, Brown AN, et al. The tetraspanin CD63 enhances the internalization of the H,K-ATPase beta-subunit. Proc. Natl. Acad. Sci. USA. 2003;
100:15560-15565
20. Fedorenko IV, Abel EV, Koomen JM, et al. Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene. 2016;
35:1225-1235
21. Flaherty KT, Lorusso PM, Demichele A, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21 -day schedule in patients with advanced cancer. Clin. Cancer Res. 2012; 18:568-576
22. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 2012; 367:1694-1703
23. Forte D, Salvestrini V, Corradi G, et al. The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling. Oncotarget. 2017; 8:2261-2274
24. Franco M, Muratori C, Corso S, et al. The tetraspanin CD151 is required for Met-dependent signaling and tumor cell growth. J. Biol. Chem. 2010; 285:38756-38764
25. Friedman AA, Amzallag A, Pruteanu-Malinici I, et al. Landscape of targeted anti-cancer drug synergies in melanoma identifies a novel BRAF-VEGFR/PDGFR combination treatment. PLoS ONE. 2015; 10: e0140310
26. Funakoshi T, Tachibana I, Hoshida Y, et al. Expression of tetraspanins in human lung cancer cells: frequent downregulation of CD9 and its contribution to cell motility in small cell lung cancer. Oncogene. 2003; 22:674-687
27. Girotti MR, Pedersen M, Sanchez-Laorden B, et al. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov. 2013; 3:158-167
28. Gustafson-Wagner E, Stipp CS. The CD9/CD81 tetraspanin complex and tetraspanin CD151 regulate α3β1 integrin-dependent tumor cell behaviors by overlapping but distinct mechanisms. PLos ONE. 2013; 8: e61834
29. Haq R, Shoag J, Andreu-Perez P, et al. Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell. 2013; 23:302-315
30. Hammond C, Denzin LK, Pan M, et al. The tetraspan protein CD82 is a resident of MHC class II compartments where it associates with HLA-DR, -DM, and -DO molecules. J. Immunol. 1998; 161:3282-3291
31. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;
380:358-365
32. Hemler ME. Targeting of tetraspanin proteins--potential benefits and strategies. Nat.
Rev. Drug Discov. 2008; 7:747-758
33. Hirabayashi J, Hashidate T, Arata Y, et al. Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim.Biophys.Acta. 2002; 1572:232-254
34. Hirata E, Girotti MR, Viros A, et al. Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling.
Cancer Cell. 2015; 27:574-588
35. Hong IK, Jeoung DI, Ha KS, et al. Tetraspanin CD151 stimulates adhesion-dependent activation of Ras, Rac, and Cdc42 by facilitating molecular association between β1 integrins and small GTPases. J. Biol. Chem. 2012; 287:32027-32039
36. Honma K, Iwao-Koizumi K, Takeshita F, et al. RPN2 gene confers docetaxel resistance in breast cancer. Nat. Med. 2008; 14:939-948
37. Hotta H, Ross AH, Huebner K, et al. Molecular cloning and characterization of an
antigen associated with early stages of melanoma tumor progression. Cancer Res. 1988;
48:2955-2962
38. Israels SJ, McMillan-Ward EM, Easton J, et al. CD63 associates with the alphaIIb beta3 integrin-CD9 complex on the surface of activated platelets. Thromb. Haemost. 2001;
85:134-141
39. Ji Z, Erin Chen Y, Kumar R, et al. MITF modulates therapeutic resistance through EGFR signaling. J. Invest. Dermatol. 2016; 135:1863-1872
40. Jung KK, Liu XW, Chirco R, et al. Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J. 2006; 25:3934-3942
41. Kazarov AR, Yang X, Stipp CS, et al. An extracellular site on tetraspanin CD151 determines alpha 3 and alpha 6 integrin-dependent cellular morphology. J. Cell Biol.
2002; 158:1299-1309
42. Khalili JS, Liu S, Rodríguez-Cruz TG, et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin -1 in melanoma.
Clin. Cancer Res. 2012; 18:5329-5340
43. Kimura A, Terao M, Kato A, et al. Upregulation of N-acetylglucosaminyltransferase-V by heparin-binding EGF-like growth factor induces keratinocyte proliferation and epidermal hyperplasia. Exp. Dermatol. 2012; 21:515-519
44. Kinoshita M, Mitsui Y, Kakoi N, et al. Common glycoproteins expressing polylactosamine-type glycans on matched patient primary and metastatic melanoma
cells show different glycan profiles. J. Proteome Res. 2014; 13:1021-1033
45. Kobuch J, Cui H, Grünwald B, et al. TIMP-1 signaling via CD63 triggers granulopoiesis and neutrophilia in mice. Haematologica. 2015; 100:1005-1013
46. Lajoie P, Partridge EA, Guay G, et al. Plasma membrane domain organization regulates EGFR signaling in tumor cells. J. Cell. Biol. 2007; 179:341-356
47. Lau KS, Partridge EA, Grigorian A, et al. Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell. 2007;
129:123-134
48. Liang Y, Eng WS, Colquhoun DR et al. Complex N-linked glycans serve as a determinant for exosome/microvesicle cargo recruitment. J. Biol. Chem. 2014;
289:32526-32537
49. Liu L, He B, Liu WM, et al. Tetraspanin CD151 promotes cell migration by regulating integrin trafficking. J. Biol. Chem. 2007; 282:31631-31642
50. Lizée G, Radvanyi LG, Overwijk WW, et al. Immunosuppression in melanoma immunotherapy: potential opportunities for intervention. Clin. Cancer Res. 2006;
12:2359-2365
51. Lupia A, Peppicelli S, Witort E, et al. CD63 tetraspanin is a negative driver of epithelial-to-mesenchymal transition in human melanoma cells. J. Invest. Dermatol.
2014; 134:2947-2956
52. Ma XH, Piao SF, Dey S, et al. J. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. Clin. Invest. 2014; 124:1406-1417
53. Maecker HT, Todd SC, Levy S. The tetraspanin superfamily: molecular facilitators.
FASEB J. 1997; 11:428-442
54. Manzano JL, Layos L, Bugés C, et al. Resistant mechanisms to BRAF inhibitors in melanoma. Ann.Transl.Med. 2016; 4:237
55. Marjon KD, Termini CM, Karlen KL, et al. Tetraspanin CD82 regulates bone marrow homing of acute myeloid leukemia by modulating the molecular organization of N-cadherin. Oncogene. 2016; 35:4132-4140
56. Montagut C, Sharma SV, Shioda T, Montagut et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 2008;
68:4853-4861
57. Mourad-Zeidan AA, Melnikova VO, Wang H, et al. Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry. Am. J. Pathol. 2008; 173:1839-1852
58. Müller J, Krijgsman O, Tsoi J, et al. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat. Commun. 2014; 5:5712
59. Nakagawa S, Arai Y, Mori H, et al. Small interfering RNA targeting CD81 ameliorated arthritis in rats. Biochem. Biophys. Res. Commun. 2009; 388:467-472
60. Nathanson KL, Martin AM, Wubbenhorst B, et al. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).
Clin. Cancer Res. 2013; 19:4868-4878
61. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2011; 468:973-977
62. Ohannesian DW, Lotan D, Thomas P, et al. Carcinoembryonic antigen and other glycoconjugates act as ligands for galectin-3 in human colon carcinoma cells. Cancer Res. 1995; 55:2191-2199
63. Paraiso KH, Xiang Y, Rebecca VW, et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 2011;
71:2750-2760
64. Park SA, Kim MJ, Park SY, et al. TIMP-1 mediates TGF-β-dependent crosstalk between hepatic stellate and cancer cells via FAK signaling. Sci. Rep. 2015; 5:16492
65. Partridge EA, Le Roy C, Di Guglielmo GM, et al. Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science. 2004; 306:120-124
66. Ploper D, Taelman VF, Robert L, et al. MITF drives endolysosomal biogenesis and potentiates Wnt signaling in melanoma cells. Proc. Natl. Acad. Sci. USA. 2014;
112:420-429
67. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 2015; 372:2006-2017
68. Poulikakos PI, Persaud Y, Janakiraman M, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011; 480:387-390
69. Prieto VG, Mourad-Zeidan AA, Melnikova V, et al. Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. Clin. Cancer Res.
2006; 12:6709-6715
70. Qiu H, Duan WM, Shu J, et al. B3GNT2, a polylactosamine synthase, regulates glycosylation of EGFR in H7721 human hepatocellular carcinom a cells. Asian Pac. J.
Cancer Prev. 2014; 15:10875-10878
71. Radford KJ, Thorne RF, Hersey P. CD63 associates with transmembrane 4 superfamily members, CD9 and CD81, and with beta 1 integrins in human melanoma. Biochem.
Biophys. Res. Commun. 1996; 222:13-18
72. Radford KJ, Thome RF, Hersey F, et al. Regulation of tumor cell motility and migration by CD63 in a human melanoma cell line. J. Immunol. 1997; 158: 3353-3358.
73. Richard G, Dalle S, Monet MA, et al. ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors. EMBO Mol. Med. 2016; 8:1143-1161.
74. Rous BA, Reaves BJ, Ihrke G, et al. Role of adaptor complex AP-3 in targeting wild-type and mutated CD63 to lysosomes. Mol. Biol. Cell. 2002; 13:1071-1082
75. Sadej R, Romanska H, Kavanagh D, et al. Tetraspanin CD151 regulates transforming growth factor beta signaling: implication in tumor metastasis. Cancer Res. 2010;
70:6059-6070
76. Sarafian V, Jadot M, Foidart JM, et al. Expression of Lamp-1 and Lamp-2 and their interactions with galectin-3 in human tumor cells. Int. J. Cancer. 1998; 75:105-111
77. Satow R, Nakamura T, Kato C; et al. ZIC5 drives melanoma aggressiveness by PDGFD-mediated activation of FAK and STAT3. Cancer Res. 2017; 77:366-377
78. Schröder J, Lüllmann-Rauch R, Himmerkus N, et al. Deficiency of the tetraspanin CD63 associated with kidney pathology but normal lysosomal function. Mol. Cell. Biol.
2009; 29:1083-1094
79. Sekulic A, Haluska P Jr, Miller AJ, et al. Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin. Proc. 2008; 83:825-846
80. Seubert B, Cui H, Simonavicius N, et al. Tetraspanin CD63 acts as a pro-metastatic factor via β-catenin stabilization. Int. J. Cancer. 2015; 136:2304-2315
81. Shen L, Yu M, Xu X, et al. Knockdown of β3GnT8 reverses 5-fluorouracil resistance in human colorectal cancer cells via inhibition the biosynthesis of polylactosamine -type N-glycans. Int. J. Oncol. 2014; 45:2560-2568
82. Silvie O, Charrin S, Billard M, et al. Cholesterol contributes to the organization of tetraspanin-enriched microdomains and to CD81-dependent infection by malaria sporozoites. J. Cell Sci. 2006; 119:1992-2002
83. Skubitz KM, Campbell KD, Iida J, et al. CD63 associates with tyrosine kinase activity and CD11/CD18, and transmits an activation signal in neutrophils. J. Immunol. 1996;
157:3617-3626
84. Smalley KS, Lioni M, Dalla Palma M, et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol. Cancer Ther.
2008; 7:2876-2883
85. Straussman R, Morikawa T, Shee K, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012; 487:500-504
86. Suzuki M, Tachibana I, Takeda Y, et al. Tetraspanin CD9 negatively regulates lipopolysaccharide-induced macrophage activation and lung inflammation. J. Immunol.
2009; 182:6485-6493
87. Takawale A, Zhang P, Patel VB, et al. Tissue inhibitor of matrix metalloproteinase-1 promotes myocardial fibrosis by mediating CD63-integrin β1 interaction. Hypertension.
2017; 69:1092-1103
88. Takeda Y, He P, Tachibana I, et al. Double deficiency of tetraspanins CD9 and CD81 alters cell motility and protease production of macrophages and causes chronic obstructive pulmonary disease-like phenotype in mice. J. Biol. Chem. 2008;
283:26089-26097
89. Takino T, Miyamori H, Kawaguchi N, et al. Tetraspanin CD63 promotes targeting and lysosomal proteolysis of membrane-type 1 matrix metalloproteinase. Biochem. Biophys.
Res. Commun. 2003; 304:160-166
90. Termini CM, Gillette JM. Tetraspanins function as regulators of cellular signaling.
Front. Cell Dev. Biol. 2017; 5:34
91. Thery C, Boussac M, Veron P. Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J. Immunol. 2001;
166:7309-7318
92. Togayachi A, Kozono Y, Ishida H, et al. Polylactosamine on glycoproteins influences basal levels of lymphocyte and macrophage activation. Proc. Natl. Acad. Sci. USA.
2007; 104:15829-15834
93. Togayachi A, Kozono Y, Kuno A, et al. Beta3GnT2 (B3GNT2), a major polylactosamine synthase: analysis of B3GNT2-deficient mice. Methods Enzymol.
2010; 479:185-204
94. Tominaga N, Hagiwara K, Kosaka N, et al. RPN2-mediated glycosylation of tetraspanin CD63 regulates breast cancer cell malignancy. Mol. Cancer. 2014; 13:134
95. Toricelli M, Melo FH, Peres GB, et al. Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3 -K signaling pathway independently of Akt phosphorylation. Mol. Cancer. 2013; 12:22
96. Trunzer K, Pavlick AC, Schuchter L, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J. Clin. Oncol. 2013;
31:1767-1774
97. van Niel G, Charrin S, Simoes S, et al. The tetraspanin CD63 regulates ESCRT-independent and -dependent endosomal sorting during melanogenesis. Dev.
Cell. 2011; 21:708-721
98. Villanueva J, Vultur A, Lee JT, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and
IGF-1R/PI3K. Cancer Cell. 2010; 18:683-695
99. Wang WC, Lee N, Aoki D, et al. The poly-N-acetyllactosamines attached to lysosomal membrane glycoproteins are increased by the prolonged association with the Golgi complex. J. Biol. Chem. 1991; 266:23185-23190
100. Wang J, Huang SK, Marzese DM, et al. Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas. J. Invest. Darmatol. 2015;
135:532-541
101. Weilner S, Keider V, Winter M, et al. Vesicular Galectin-3 levels decrease with donor age and contribute to the reduced osteo-inductive potential of human plasma derived extracellular vesicles. Aging. 2016; 8:1156-1157
102. Wilson TR, Fridlyand J, Yan Y, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 2012; 487:505-509
103. Yadav V, Burke TF, Huber L, et al. The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.
Mol. Cancer Ther. 2014; 13:2253-2263
104. Yang X, Kovalenko OV, Tang W, et al. Palmitoylation supports assembly and function of integrin-tetraspanin complexes. J. Cell Biol. 2004; 167:1231-1240
105. Yamazaki N, Kiyohara Y, Uhara H, et al. Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study. Cancer Sci.
2017; 108:1223-1230
106. Yoshida T, Kawano Y, Sato K, et al. A CD63 mutant inhibits T-cell tropic human immunodeficiency virus type 1 entry by disrupting CXCR4 trafficking to the plasma membrane. Traffic. 2008; 9:540-558
107. Yoshida T, Ebina H, Koyanagi Y. N-linked glycan-dependent interaction of CD63 with CXCR4 at the Golgi apparatus induces downregulation of CXCR4. Microbiol. Immunol.
2009; 53:629-635
108. Yoshida A, Lee EK, Diehl JA. Induction of therapeutic senescence in vemurafenib-resistant melanoma by extended inhibition of CDK4/6. Cancer Res. 2016;
76:2990-3002